Ascendis Pharma A/S

ASND Healthcare Biotechnology

Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.

Revenue
+119.9%
EPS
+612.3%
Free cash flow
+2,335.9%
Total debt
−41.8%

Quarter to June 2026, against a year earlier

257.99 4.54 +1.79%
Market cap
$16.6B
P/E
18.3×
Fwd P/E
15.4×
Dividend yield
—
F-score
5/9
Altman Z
2.02
Beneish M
−2.51
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
7 6 5 5

+8 more TTM periods

ROE
118.44% 311.60% 172.80% 164.31%
ROA
44.34% 33.40% (18.76%) (19.99%)
ROIC
15.07% (1.01%) (91.65%) (82.72%)
Return on Tangible Assets
69.94% 375.74% (122.55%) (164.00%)
Average Days of Receivables
78.46 84.24 79.93 86.95
Free Cash Flow per Share
6.02 0.80 0.85 (1.97)
Free Cash Flow
387.49 49.14 51.38 (119.66)
Other line items

Show all line items

Columns are period end dates